0
Abstract: Slide Presentations |

Clinical Markers of Worsening Asthma With the Fluticasone Propionate/Salmeterol 100/50 mcg Diskus® (FSC) vs Fluticasone propionate (FP) 250 mcg Alone in Patients Requiring FP 250 mcg BID for Asthma Stability FREE TO VIEW

Paul M. Dorinsky, MD; Steve W. Yancey, MS; Kelli Waitkus-Edwards, PhD; Lisa Edwards, PhD
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest


Chest. 2003;124(4_MeetingAbstracts):88S. doi:10.1378/chest.124.4_MeetingAbstracts.88S
Text Size: A A A
Published online

Abstract

PURPOSE:  This post-hoc analysis examined clinical markers of worsening asthma with FSC 100/50 BID versus FP 250 BID in patients who required FP 250 BID for asthma control.

METHODS:  Data from two replicate, double-blind, parallel group, equivalence studies were evaluated. Patients requiring FP 250 BID for asthma stability were randomized to FSC 100/50 or FP 250 BID for 12–24 weeks. For subjects who developed worsening asthma, patient-evaluated morning/evening PEF, albuterol use, and asthma symptom scores were analyzed for 14 days prior to the development of worsening asthma as defined by: ≥20% decrease in FEV1, ≥20% decrease in AM PEF on 3 consecutive days, or an asthma exacerbation.

RESULTS:  ParameterWeeks 1–12Weeks 13–24FSC 100/50 BID (n=572)FP 250 BID (n=552)FSC 100/50 BID (n=269)FP 250 BID (n=240)Worsening asthma*35 (6%)53(10%)17(6%)17 (7%) ≥20% decrease in FEV1162066 ≥20% decrease in AM PEF61755 Asthma141564 Exacerbation Investigator21212 Discretion*

Patients may have met more than one criterion for worsening asthma.

Fewer FSC vs FP patients developed worsening asthma and no patient in either group developed an exacerbation requiring hospitalization. The percentage of patients withdrawn due to worsening asthma based on FEV1 or AM PEF were comparable in both groups over the study period (63–65% in each group). The pattern of changes in PEF, albuterol use, and asthma symptoms was similar.CONCLUSIONS: Among patients requiring FP 250 BID for asthma stability, FSC was ICS-sparing allowing a 60% reduction in ICS dose while reducing the overall incidence of worsening asthma. The pattern of worsening asthma did not differ in patients treated with FSC versus higher dose FP alone.

CLINICAL IMPLICATIONS:  Though fewer FSC patients developed worsening asthma, the pattern of decline in clinical parameters preceding an exacerbation was similar for both groups, suggesting that both clinicians and patients can follow a standard action plan for detecting and treating exacerbations.

DISCLOSURE:  P.M. Dorinsky, I am an employee of GSK, Industry.

Monday, October 27, 2003

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543